Mostrar el registro sencillo del ítem
dc.contributor.author | Laguno, M | |
dc.contributor.author | Von Wichmann, MA | |
dc.contributor.author | Van den Eynde, E | |
dc.contributor.author | Navarro, J | |
dc.contributor.author | Cifuentes Luna, Carmen | |
dc.contributor.author | Murillas Angoiti, Javier | |
dc.contributor.author | Veloso, S | |
dc.contributor.author | Martinez-Rebollar, M | |
dc.contributor.author | Guardiola, JM | |
dc.contributor.author | Jou, A | |
dc.contributor.author | Gomez-Sirvent, J. L | |
dc.contributor.author | Cervantes, M | |
dc.contributor.author | Pineda, JA | |
dc.contributor.author | Lopez-Calvo, S | |
dc.contributor.author | Carrero, A | |
dc.contributor.author | Montes, ML | |
dc.contributor.author | Deig, Elisabeth | |
dc.contributor.author | Tapiz, A | |
dc.contributor.author | Ruiz-Mesa, JD | |
dc.contributor.author | Cruceta, A | |
dc.contributor.author | de Lazzari, Ellsa | |
dc.contributor.author | Mallolas, J | |
dc.date.accessioned | 2024-07-09T09:12:59Z | |
dc.date.available | 2024-07-09T09:12:59Z | |
dc.date.issued | 2016-12 | |
dc.identifier.citation | Laguno M, Von Wichmann MA, Van Den Eynde E, Navarro J, Cifuentes Luna C, Murillas Angoiti J, et al. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. Int J Infect Dis. 2016 Dec;53:46-51. Epub 2016 Nov 1. | en |
dc.identifier.issn | 1201-9712 | |
dc.identifier.other | http://hdl.handle.net/20.500.13003/17296 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/20233 | |
dc.description.abstract | Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-alpha 2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. Methods: This was a phase III prospective trial. HIV-HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug. Results: From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients). Conclusions: Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe that this combination can be beneficial in situations where new HCV direct antiviral agent interferonfree therapies are not available yet. | en |
dc.description.sponsorship | Funded by Merck: BOC-HIV Study.Maria Martinez-Rebollar is funded by a grant Sara Borrell, CM13-00123, from Instituto de Salud Carlos III, Ministerio Economia y Competitividad. - Other authors declare no other conflict of interest. | es_ES |
dc.language.iso | eng | en |
dc.publisher | Elsevier | en |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | PEG-IFN/RBV plus BOC therapy | |
dc.subject | HIV-HCV experienced patients | |
dc.subject | HCV genotype 1 | |
dc.subject | Re-treatment | |
dc.subject.mesh | Viral Nonstructural Proteins | * |
dc.subject.mesh | Genotype | * |
dc.subject.mesh | Hepacivirus | * |
dc.subject.mesh | Retreatment | * |
dc.subject.mesh | Polyethylene Glycols | * |
dc.subject.mesh | Spain | * |
dc.subject.mesh | Adult | * |
dc.subject.mesh | Antiviral Agents | * |
dc.subject.mesh | Hepatitis C | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Drug Therapy, Combination | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Recombinant Proteins | * |
dc.subject.mesh | HIV Infections | * |
dc.subject.mesh | Male | * |
dc.subject.mesh | Prospective Studies | * |
dc.subject.mesh | Female | * |
dc.subject.mesh | Coinfection | * |
dc.subject.mesh | Treatment Outcome | * |
dc.subject.mesh | Proline | * |
dc.subject.mesh | Interferon-alpha | * |
dc.subject.mesh | Ribavirin | * |
dc.title | Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study | en |
dc.type | research article | en |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 International | * |
dc.identifier.pubmedID | 27815225 | es_ES |
dc.format.volume | 53 | es_ES |
dc.format.page | 46-51 | es_ES |
dc.identifier.doi | 10.1016/j.ijid.2016.10.028 | |
dc.identifier.e-issn | 1878-3511 | es_ES |
dc.relation.publisherversion | https://dx.doi.org/10.1016/j.ijid.2016.10.028 | en |
dc.identifier.journal | International Journal of Infectious Diseases | es_ES |
dc.rights.accessRights | open access | en |
dc.subject.decs | Prolina | * |
dc.subject.decs | Resultado del Tratamiento | * |
dc.subject.decs | Coinfección | * |
dc.subject.decs | Polietilenglicoles | * |
dc.subject.decs | Interferón-alfa | * |
dc.subject.decs | Femenino | * |
dc.subject.decs | Infecciones por VIH | * |
dc.subject.decs | Masculino | * |
dc.subject.decs | Quimioterapia Combinada | * |
dc.subject.decs | Hepatitis C | * |
dc.subject.decs | Humanos | * |
dc.subject.decs | Persona de Mediana Edad | * |
dc.subject.decs | Estudios Prospectivos | * |
dc.subject.decs | Genotipo | * |
dc.subject.decs | Proteínas Recombinantes | * |
dc.subject.decs | Proteínas no Estructurales Virales | * |
dc.subject.decs | Antivirales | * |
dc.subject.decs | Adulto | * |
dc.subject.decs | Ribavirina | * |
dc.subject.decs | Hepacivirus | * |
dc.subject.decs | Retratamiento | * |
dc.subject.decs | España | * |
dc.identifier.scopus | 2-s2.0-84997050481 | |
dc.identifier.wos | 389516700011 | |
dc.identifier.pui | L613310152 |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |